title: Strong neuroprotection with a novel platinum nanoparticle against ischemic stroke- and tissue plasminogen activator-related brain damages in mice.
abstract: Reactive oxygen species (ROS) are major exacerbation factor in acute ischemic stroke, and thrombolytic agent tissue plasminogen activator (tPA) may worsen motor function and cerebral infarcts. The platinum nanoparticle (nPt) is a novel ROS scavenger, and thus we examined the clinical and neuroprotective effects of nPt in ischemic mouse brains. Mice were subjected to transient middle cerebral artery occlusion (tMCAO) for 60 min and divided into the following four groups by intravenous administration upon reperfusion, vehicle, tPA, tPA+nPt, and nPt. At 48 h after tMCAO, motor function, infarct volume, immunohistochemical analyses of neurovascular unit (NVU), in vivo imaging of matrix metalloproteinase (MMP), and zymography for MMP-9 activity were examined. Superoxide anion generation at 2h after tMCAO was also examined with hydroethidine (HEt). As a result, administration of tPA deteriorated the motor function and infarct volume as compared to vehicle. In vivo optical imaging of MMP showed strong fluorescent signals in affected regions of tMCAO groups. Immunohistochemical analyses revealed that tMCAO resulted in a minimal decrease of NAGO and occludin, but a great decrease of collagen IV and a remarkable increase of MMP-9. HEt stain showed increased ROS generation by tMCAO. All these results became pronounced with tPA administration, and were greatly reduced by nPt. The present study demonstrates that nPt treatment ameliorates neurological function and brain damage in acute cerebral infarction with neuroprotective effect on NVU and inactivation of MMP-9. The strong reduction of ROS production by nPt could account for these remarkable neurological and neuroprotective effects against ischemic stroke.
authors: Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. motonori@cc.okayama-u.ac.jp
authors: M
authors: M
authors: Takamiya
authors: Y
authors: Y
authors: Miyamoto
authors: T
authors: T
authors: Yamashita
authors: K
authors: K
authors: Deguchi
authors: Y
authors: Y
authors: Ohta
authors: K
authors: K
authors: Abe
mesh_terms: D000818:Animals; D020520:Brain Infarction / Q000139:chemically induced* / Q000517:prevention & control*; D024141:Collagen Type IV / Q000378:metabolism; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy*; D017078:Laser-Doppler Flowmetry; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D053768:Metal Nanoparticles / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D009069:Movement Disorders / Q000209:etiology / Q000517:prevention & control; D010617:Phenanthridines / Q000378:metabolism; D010984:Platinum / Q000627:therapeutic use*; D017382:Reactive Oxygen Species / Q000378:metabolism; D012039:Regional Blood Flow / Q000187:drug effects; D015424:Reperfusion; D019265:Spectroscopy, Near-Infrared; D013481:Superoxides / Q000378:metabolism; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*
chemical_list: D024141:Collagen Type IV; D010617:Phenanthridines; D017382:Reactive Oxygen Species; D013481:Superoxides; C058428:hydroethidine; D010984:Platinum; D010959:Tissue Plasminogen Activator; D020780:Matrix Metalloproteinase 9